RU2750727C9 - Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там - Google Patents

Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там Download PDF

Info

Publication number
RU2750727C9
RU2750727C9 RU2017139515A RU2017139515A RU2750727C9 RU 2750727 C9 RU2750727 C9 RU 2750727C9 RU 2017139515 A RU2017139515 A RU 2017139515A RU 2017139515 A RU2017139515 A RU 2017139515A RU 2750727 C9 RU2750727 C9 RU 2750727C9
Authority
RU
Russia
Prior art keywords
hydrogen
group
methyl
alkyl
occurrence
Prior art date
Application number
RU2017139515A
Other languages
English (en)
Russian (ru)
Other versions
RU2017139515A3 (ko
RU2017139515A (ru
RU2750727C2 (ru
Inventor
Кийян НАМ
Джэсын КИМ
Сохён АН
Еджин ЧОН
Духён ЛИ
Донсик ПАРК
Ёнин ЯН
Сэён ЛИ
Чонджун КИМ
Чийе АН
Хана КИМ
Чон-Вон ЧЖУН
Карстен ШУЛЬЦ-ФАДЕМРЕХТ
Original Assignee
Кьюриент Ко., Лтд.
Лид Дискавери Сентер Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кьюриент Ко., Лтд., Лид Дискавери Сентер Гмбх filed Critical Кьюриент Ко., Лтд.
Publication of RU2017139515A publication Critical patent/RU2017139515A/ru
Publication of RU2017139515A3 publication Critical patent/RU2017139515A3/ru
Application granted granted Critical
Publication of RU2750727C2 publication Critical patent/RU2750727C2/ru
Publication of RU2750727C9 publication Critical patent/RU2750727C9/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2017139515A 2015-04-14 2016-04-14 Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там RU2750727C9 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562147262P 2015-04-14 2015-04-14
US62/147,262 2015-04-14
US201562147925P 2015-04-15 2015-04-15
US62/147,925 2015-04-15
PCT/EP2016/058284 WO2016166250A1 (en) 2015-04-14 2016-04-14 Quinoline derivatives as tam rtk inhibitors

Publications (4)

Publication Number Publication Date
RU2017139515A RU2017139515A (ru) 2019-05-14
RU2017139515A3 RU2017139515A3 (ko) 2019-07-17
RU2750727C2 RU2750727C2 (ru) 2021-07-01
RU2750727C9 true RU2750727C9 (ru) 2021-08-16

Family

ID=55752298

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017139515A RU2750727C9 (ru) 2015-04-14 2016-04-14 Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там

Country Status (20)

Country Link
US (1) US10934274B2 (ko)
EP (1) EP3286177B1 (ko)
JP (2) JP6654646B2 (ko)
KR (1) KR102499359B1 (ko)
CN (1) CN107667101B (ko)
AU (1) AU2016249860B2 (ko)
BR (1) BR112017021929B1 (ko)
CA (1) CA2980652C (ko)
DK (1) DK3286177T3 (ko)
ES (1) ES2807851T3 (ko)
HK (1) HK1243707A1 (ko)
HU (1) HUE049856T2 (ko)
IL (1) IL254898B (ko)
MX (1) MX2017013144A (ko)
MY (1) MY196078A (ko)
PH (1) PH12017501822A1 (ko)
RU (1) RU2750727C9 (ko)
SG (1) SG11201707638UA (ko)
WO (1) WO2016166250A1 (ko)
ZA (1) ZA201706380B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151786A1 (en) 2016-03-01 2017-09-08 University Of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
JP7058265B2 (ja) * 2017-05-11 2022-04-21 クミアイ化学工業株式会社 ピラゾール－３－カルボン酸アミド誘導体及び有害生物防除剤
CN109896997A (zh) * 2017-12-08 2019-06-18 中国药科大学 N－酰基苯胺类c－Met激酶抑制剂的制备方法及其用途
IL275490B2 (en) 2017-12-22 2024-05-01 Ravenna Pharmaceuticals Inc Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2019184918A1 (zh) * 2018-03-27 2019-10-03 暨南大学 3-氨基吡唑类化合物及其应用
CN112313216A (zh) 2018-05-30 2021-02-02 奎利恩特有限公司 作为axl/mer rtk和csf1r的抑制剂的喹啉衍生物
CN110857293B (zh) * 2018-08-24 2023-01-10 药捷安康(南京)科技股份有限公司 一种新型的喹啉衍生物抑制剂
CN111053771A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 用于治疗食道鳞状细胞癌的喹啉类化合物或其药学上可接受的盐
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023283369A1 (en) * 2021-07-08 2023-01-12 Vibliome Therapeutics, Llc Modulators of protein kinases
TW202333709A (zh) 2021-12-16 2023-09-01 美商奇奈特生物製藥公司 Met激酶抑制劑
WO2023183444A1 (en) * 2022-03-24 2023-09-28 Vibliome Therapeutics, Llc Modulators of protein kinases
CN117624128A (zh) * 2022-08-30 2024-03-01 药捷安康(南京)科技股份有限公司 喹啉衍生物抑制剂的晶型及其制备方法及用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013231B1 (ru) * 2005-04-27 2010-04-30 Амген Инк. Замещенные амидные производные в качестве ингибиторов протеинкиназы
US20140018365A1 (en) * 2010-08-28 2014-01-16 Max-Planck-Gesellschaft Zur Förderung Der Wissenscchaften E.V. Pharmaceutically active compounds as axl inhibitors
RU2013135662A (ru) * 2011-02-28 2015-04-10 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080004273A1 (en) * 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity
EP2780338B1 (en) * 2011-11-14 2016-11-09 Ignyta, Inc. Uracil derivatives as axl and c-met kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013231B1 (ru) * 2005-04-27 2010-04-30 Амген Инк. Замещенные амидные производные в качестве ингибиторов протеинкиназы
US20140018365A1 (en) * 2010-08-28 2014-01-16 Max-Planck-Gesellschaft Zur Förderung Der Wissenscchaften E.V. Pharmaceutically active compounds as axl inhibitors
RU2013135662A (ru) * 2011-02-28 2015-04-10 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. PAOLINO et al. "The E3 ligase Cbl-b and TAM receptor regulate cancer metastasis via natural killer cells", Nature, 2014, vol. 507, pp. 508-512. *
Q. TANG et al. " Design, Synthesis, and structure-activity relationship of novel 6,7-disubstitute-4-phenoxyquinoline-derivatives as potential antitumor agents", European Journal of Medicinal Chemistry, 2013, vol. 69, pp. 77-89. *

Also Published As

Publication number Publication date
BR112017021929B1 (pt) 2023-05-09
EP3286177B1 (en) 2020-05-06
MX2017013144A (es) 2018-07-06
PH12017501822A1 (en) 2018-04-23
KR20170135971A (ko) 2017-12-08
JP6654646B2 (ja) 2020-02-26
IL254898A0 (en) 2017-12-31
BR112017021929A2 (pt) 2018-07-03
RU2017139515A3 (ko) 2019-07-17
IL254898B (en) 2020-11-30
JP2020012001A (ja) 2020-01-23
HUE049856T2 (hu) 2020-10-28
AU2016249860B2 (en) 2019-10-10
WO2016166250A1 (en) 2016-10-20
EP3286177A1 (en) 2018-02-28
JP2018511624A (ja) 2018-04-26
AU2016249860A1 (en) 2017-10-12
KR102499359B1 (ko) 2023-02-10
US20180093968A1 (en) 2018-04-05
RU2017139515A (ru) 2019-05-14
CN107667101B (zh) 2021-07-30
DK3286177T3 (da) 2020-06-08
ES2807851T3 (es) 2021-02-24
US10934274B2 (en) 2021-03-02
SG11201707638UA (en) 2017-10-30
CA2980652C (en) 2021-04-27
ZA201706380B (en) 2022-03-30
CA2980652A1 (en) 2016-10-20
MY196078A (en) 2023-03-13
HK1243707A1 (zh) 2018-07-20
RU2750727C2 (ru) 2021-07-01
CN107667101A (zh) 2018-02-06

Similar Documents

Publication Publication Date Title
RU2750727C9 (ru) Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там
US8999982B2 (en) Pharmaceutically active compounds as Axl inhibitors
KR101941929B1 (ko) 2-아미노피리미딘계 화합물 및 이의 약물 조성물과 응용
JP6380777B2 (ja) ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物
WO2020024997A1 (zh) 一类具有免疫调节功能的含n杂环化合物的制备和应用
JP2023168629A (ja) Ａｘｌ／ｍｅｒ ｒｔｋおよびｃｓｆ１ｒの阻害剤としてのキノリン誘導体
CN110128425B (zh) 作为pi3k/mtor抑制剂的芳环或杂环取代的稠合喹啉化合物
KR20110025856A (ko) 오로라 키나아제 억제제로서 나프티리디니논
WO2022117090A1 (zh) 一种多环化合物及其制备方法和用途
WO2024002378A1 (zh) 一类具有激酶抑制功能的化合物及其制备和应用

Legal Events

Date Code Title Description
TH4A Reissue of patent specification